Letter to the Editor| Volume 40, ISSUE 2, P358, February 2004

Ineffectiveness of hepatitis B vaccination in lamivudine-treated cirrhotics

      Treatment with lamivudine (LAM) rapidly inhibits viral replication in most patients with chronic liver disease related to hepatitis B virus (HBV), but the development of drug-resistant viral mutants [
      • Lagget M.
      • Rizzetto M.
      Treatment of chronic hepatitis B.
      ] limits its long-term effectiveness.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lagget M.
        • Rizzetto M.
        Treatment of chronic hepatitis B.
        Curr Pharm Des. 2002; 8: 953-958
        • Bienzle U.
        • Gunther M.
        • Neuhaus R.
        • Neuhaus P.
        Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results.
        Liver Transpl. 2002; 8: 562-564
        • Sanchez-Fueyo A.
        • Rimola A.
        • Grande L.
        • Costa J.
        • Mas A.
        • Navasa M.
        • et al.
        Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
        Hepatology. 2000; 31: 496-501
        • Boni C.
        • Penna A.
        • Oggs G.S.
        • Bertoletti A.
        • Pilli M.
        • Cavallo C.
        • et al.
        Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
        Hepatology. 2001; 33: 963-971
        • Pol S.
        • Nalpas B.
        • Driss F.
        • Michel M.L.
        • Tiollais P.
        • Denis J.
        • Brecho C.
        Efficacy and limitations of a specific immunotherapy in chronic hepatitis B.
        J Hepatol. 2001; 34: 917-921
        • Senturk H.
        • Tabak F.
        • Akdogan M.
        • Erdem L.
        • Mert A.
        • Ozaras R.
        • et al.
        Therapeutic vaccination in chronic hepatitis B.
        Gastroenterol Hepatol. 2002; 17: 72-76
        • Locarnini S.A.
        Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance.
        Hepatology. 1998; 27: 294-297
        • Torresi J.
        • Earnest-Silveira L.
        • Deliyannis G.
        • Edgtton K.
        • Zhuang H.
        • Locarnini S.A.
        • Fyfe J.
        Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.
        Virology. 2002; 293: 305-313
        • Torresi J.
        The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus.
        J Clin Virol. 2002; 25: 97